Clinical trials: Chronic Hepatitis B Infections
Hepatitis B, Chronic
A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment
The purpose of this study is to assess the incidence of participants who reach hepatitis B surface antigen (HBsAg) seroclearance after discontinuing nucleos(t)ide analog (NA) therapy in participants with HBsAg less than or equal…
- Trial name
- SALMONS (NCT05550519)
- Testing
- Entecavir (ETV), Tenofovir Disoproxil Fumarate (TDF), Tenofovir Alafenamide (TAF)
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Hepatitis B
A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects
A randomized study of ALG-125755 to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics after single doses in healthy volunteers, and single and multiple doses in CHB subjects
- Trial name
- NCT05561530
- Testing
- ALG-125755
- Where
- 4 sites in Bulgaria, Moldova and 2 more
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Aligos Therapeutics
Chronic Hepatitis B Virus Infection
Antiviral Therapy for Patients With Chronic Hepatitis B Infection
The study aims to demonstrate that antiviral therapy for patients with immune tolerance of CHB. On the basis of the original antiviral therapy of entecavir, further clarify the safety and effectiveness of entecavir combined with…
- Trial name
- NCT05382351
- Testing
- Entecavir, Entecavir combined with Tenofovir Amibufenamide
- Where
- China
- Volunteers
- 238 people
- Sponsor
- Sun Yat-sen University
Hepatitis B, Chronic
An Open Label, Multi Centre Phase IV Study of Adefovir Dipivoxil in Korean Patients With Chronic Hepatitis B (CHB)
Objective(s) The primary study objective is to assess the antiviral effect of 12 weeks of adefovir dipivoxil treatment in Korean patients with chronic hepatitis B and compensated liver disease.
- Trial name
- NCT01205165
- Testing
- Adefor dipivoxil
- Volunteers
- 104 people
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
The Norwegian Nucleoside Analogue Stop Study
Globally, an estimated 257 million individuals have chronic hepatitis B-virus infection (CHB). In the absence of treatment 15-40% of these will progress to liver cirrhosis and/or hepatocellular carcinoma.
- Trial name
- Nuc-Stop (NCT03681132)
- Testing
- Stop of therapy
- Where
- 11 sites in Denmark, Ethiopia and 2 more
- Volunteers
- 127 people
- Sponsor
- Oslo University Hospital
Hepatitis B, Chronic, Hepatocellular Carcinoma
PROLIFICA - West African Treatment Cohort for Hepatitis B
The West African Treatment Cohort for Hepatitis B (WATCH) study is a component of the European Commission Funded FP7 project PROLIFICA.
- Trial name
- WATCH (NCT02129829)
- Testing
- Tenofovir disoproxil
- Where
- 2 sites in Senegal, The Gambia
- Volunteers
- 1,079 people
- Sponsor
- Imperial College London
Chronic Hepatitis B
Sustained Viral Response in Patients Achieved HBsAg Level≤100 IU/ml After Completed Interferon Treatment
Chronic hepatitis B (CHB) is a serious liver disease worldwide, and the leading cause of cirrhosis and hepatocellular carcinoma (HCC).
- Trial name
- NCT02348502
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Beijing Ditan Hospital
Hepatitis B, Chronic
Efficacy of NA Combined With PEG-IFN-α2b in the Continuous Versus Pulsed Treatment of Patients With Chronic Hepatitis B
Previous studies have shown that there are alterations in the number and affinity of interferon receptors during interferon therapy and that such alterations recover to varying degrees some time after the end of treatment.
- Trial name
- EPCP (NCT05922306)
- Testing
- PEGylated recombinant human interferon alpha-2b injection
- Where
- China
- Volunteers
- 1,084 people
- Sponsor
- Anhui Medical University
Chronic Hepatitis B
Health Promotion and Management for Hepatitis B Carriers
The investigators propose a project of preventive medicine with concern of local context in Taiwan. The target population includes all staff and faculty members, students, and alumni of a university in Northern Taiwan, with…
- Trial name
- NCT01065363
- Testing
- standardized exercise program and dietary counseling
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis B
HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated
Hepatitis B surface antigen loss/seroconversion, considered to be the ideal outcome of chronic hepatitis B virus (HBV) infection, occurs spontaneously at a low rate in inactive carriers.
- Trial name
- NCT01471535
- Testing
- Pegylated interferon alfa-2a
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Ditan Hospital
Chronic Hepatitis B
Procurement of Blood Samples for a Biomedical Research Program on T Cell Functional Response to Chronic HBV Infection
The objective of the study is to procure blood (plasma, serum, RNA and PBMC samples) from approximately 40 chronic HBV for biomedical research program led by VGTI Florida.
- Trial name
- NCT02017587
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Vaccine and Gene Therapy Institute, Florida
Chronic Hepatitis B
A Efficacy and Safety Study of Adefovir Dipivoxil to Treat Chinese Patients With HBeAg+ve Chronic Hepatitis B
The purpose of this study is to determine whether Adefovir Dipivoxil is effective and safe in treatment of Chinese Patients with HBeAg positive Chronic Hepatitis B for 5 years.
- Trial name
- NCT00857675
- Testing
- AAAA, AAPA, PAAA
- Where
- 10 sites in China
- Volunteers
- 480 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B
Combined Use of Bacteroides Fragilis and BCAAs on HBsAg Clearance
The goal of this prospective observational study is to determine the effects of concomitant administration of Bacteroides fragilis and Branched-Chain Amino Acids on hepatitis B virus clearance.
- Trial name
- NCT07257562
- Testing
- PegIFNα2b+Nucleoside analog, PegIFNα2b+Nucleoside analog+Bacteroides fragilis+Branched-Chain Amino Acids
- Where
- China
- Volunteers
- 40 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Chronic Hepatitis B
Sequential PD-1 Antibody and Pegylated Interferon Therapy for Nucleos(t)Ide Analogue-suppressed Chronic Hepatitis B
This is a prospective, multicenter, randomized, open-label controlled clinical trial designed to evaluate the efficacy and safety of a sequential treatment strategy incorporating a PD-1 antibody and pegylated interferon-α…
- Trial name
- NCT07809165
- Testing
- Sintilimab, Pegylated Interferon-α 2b, Nucleos(t)ide Analogues
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Beijing 302 Hospital
HBeAg-negative Chronic Hepatitis B
Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen
The primary objective of this study is to compare the efficacy, safety, and tolerability of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF) in treatment-naive and treatment-experienced adults with hepatitis…
- Trial name
- NCT01940341
- Testing
- TAF, TDF
- Where
- 105 sites in United States, Australia and 15 more
- Volunteers
- 426 people
- Sponsor
- Gilead Sciences
Hepatitis B, Chronic
Pharmacokinetic (PK) Profiles of Tenofovir Disoproxil Fumarate (TDF) 300 mg in Healthy Chinese Subjects
This study will evaluate the pharmacokinetic profile of tenofovir disoproxil fumarate (TDF) 300 mg in Chinese subjects to support the registration of this compound in the People's Republic of China.
- Trial name
- PK of TDF (NCT01480622)
- Testing
- TDF tablets
- Where
- China
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B
To Optimize the Therapeutic Pathway of Peginterferon Treatment in Patients With CHB Based on IFNA2p.Ala120Thr /ISGs.
The study is to guide clinical cure of peginterferon alfa-2a treatment in patients with chronic hepatitis B based on the detection of interferon gene mutation (IFNA2p.Ala120Thr) and interferon-stimulated genes (ISGs) detection…
- Trial name
- IFNA2/ISGs (NCT03771677)
- Testing
- Nucleotide Analog, Interferon Alfa-2A
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Sun Yat-sen University
Chronic Hepatitis b
Phase IIIB Extension Clinical Trial of Efficacy and Safety of GST-HG141 (Nairevir) Combined With NAs in Chronic Hepatitis B
This is a multicenter, single-arm, open-label, phase IIIb extension clinical trial designed to evaluate the long-term safety and tolerability of GST-HG141 (nerlecovir, 50 mg BID) in combination with nucleos(t)ide analogues (NAs)…
- Trial name
- NCT07588009
- Testing
- GST-HG141
- Volunteers
- 576 people
- Sponsor
- Fujian Akeylink Biotechnology Co., Ltd.
Adoptive Treatment for Hepatitis B With γδT Cells
"Treatment of Active HBV With γδT Cells" Clinical Trial Protocol
To evaluate the safety and anti-HBV efficacy of γδT cells.
- Trial name
- NCT03113058
- Testing
- Adoptive transfer of γδT cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jinan University Guangzhou
Chronic Hepatitis B
Switch From Adefovir to Tenofovir in Chronic Hepatitis B for Suboptimal Response to Adefovir-based Combination Therapy
In Korea, the number of suboptimal responders to rescue combination therapy is also increasing. As a matter of fact, according to the investigations in Korea, HBV DNA undetectability at 48 weeks of adefovir and lamivudine…
- Trial name
- NCT01595633
- Testing
- Switching from adefovir (10mg/day) to tenofovir (300mg/day)
- Where
- South Korea
- Volunteers
- 124 people
- Sponsor
- Yonsei University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.